Cardiology in contemporary China: An update

International Journal of Cardiology

Volumn 126, Issue 2, 2008, Pages 147-159

  Cheng, Tsung O ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CARDIOVASCULAR DISEASE; CHINA; CHINESE MEDICINE; CLINICAL PRACTICE; CLINICAL RESEARCH; EDITORIAL; HISTORY OF MEDICINE; HUMAN; MEDICAL PRACTICE; NANOMEDICINE; PRIORITY JOURNAL;

CARDIOLOGY; CHINA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICINE, CHINESE TRADITIONAL; PORTRAITS AS TOPIC;

EID: 42649091470     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.07.030     Document Type: Editorial

References (103)

1. Cheng T.O. The current state of cardiology in China. Int J Cardiol 96 (2004) 425-439
2. Conti C.R. Chinese cardiology. Clin Cardiol 30 (2007) 212-213
3. Cheng T.O. The evolution of cardiology in China. In: Wan S., and Yim A.P.C. (Eds). Cardiothoracic Surgery in China: Past, Present, and Future (2007), Chinese University of Hong Kong, Hong Kong 204-305
4. Cheng T.O. Second Annual Paul D. White Lecture - Cardiology in People's Republic of China. In: Russek H.I. (Ed). New Horizons in Cardiovascular Practice (1975), University Park Press, Baltimore 1-27
5. Mervis J. China's unique environment favors large intervention trials. Science 270 (1995) 1149-1151
6. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 366 (2005) 1607-1621
7. Cheng T.O. China's role in international cardiology. J Am Coll Cardiol 48 (2006) 224-225
8. Jiang S.L., Ji X.P., Zhang C., Wang X.R., Zhang M., and Zhang Y. Impact of Chinese guidelines for management of patients with acute myocardial infarction on outcomes of hospitalized patients. Chin Med J 119 (2006) 26-31
9. Cheng T.O., and Julian D. Acronyms of cardiologic trials - 2002. Int J Cardiol 91 (2003) 261-351
10. Woo K.S., Chook P., Qiao M., et al. Job stress, westernized dietary habits and subclinical atherosclerosis: report from CATHAY study. Eur Heart J 22 Abstract Suppl (2001) 375
11. CHANCE Study Group. The immediate and long-term prognosis following unprotected left main coronary artery stenting in Chinese - Chinese Registry of Unprotected Left Main Coronary Artery Stenting (CHANCE Study). Chin J Cardiol 33 (2005) 210-213
12. Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A., and FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23 (2005) 2157-2172
13. Gong L., Zhang W., Zhu Y., et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 14 (1996) 1237-1245
14. Chen A.F., and Su D.F. A new season of Chinese cardiovascular pharmacology research. Acta Pharmacol Sin 26 (2005) 265-278
15. Wang B.H., and Ou-Yang J.P. Pharmacological actions of sodium ferulate in cardiovascular system. Cardiovasc Drug Rev 23 (2005) 161-172
16. Xu F.P., Chen M.S., Wang Y.Z., et al. Leptin induces hypertrophy via endothelin-l-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110 (2004) 1269-1275
17. Wang G.L., Wang X.R., Lin M.J., He H., Lan X.J., and Guan Y.Y. Deficiency in CIC-3 chloride channels prevents rat aortic smooth muscle cell proliferation. Circ Res 91 (2002) e28-e32
18. Wang H.Y., Gao P.J., Ji K.D., et al. Circulating endothelial progenitor cells, C-reactive protein and severity of coronary stenosis in Chinese patients with coronary artery disease. Hypertens Res 30 (2007) 133-141
19. Ma Z.Y., Li L., Zhong X.Z., et al. Cilnidipine improves left-ventricular midwall function independently of blood pressure changes in Chinese patients with hypertension. J Cardiovasc Pharmacol 49 (2007) 33-38
20. Zhao S.P., Lu Z.L., Du B.M., et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol 49 (2007) 81-84
21. Gu D., Wildman R.P., Wu X., et al. Incidence and predictors of hypertension over 8 years among Chinese men and women. J Hypertens 25 (2007) 517-523
22. Zhang C., Yin W., Liao D., et al. NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs. J Lipid Res 47 (2006) 2055-2063
23. Zhang H.S., and Wang S.Q. Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha (TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. J Mol Cell Cardiol 41 (2006) 138-148
24. Zhang W.D., Zhang C., Liu R.H., et al. Preclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs. Life Sci 79 (2006) 808-815
25. Yan L.P., Chan S.W., Chan A.S., Chen S.L., Ma X.J., and Xu H.X. Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci 79 (2006) 324-330
26. Wang W., Hu G.Y., and Wang Y.P. Selective modulation of L-type calcium current by magnesium lithospermate B in guinea-pig ventricular myocytes. Life Sci 78 (2006) 2989-2997
27. Zhang Y., Zhu H., Ye G., et al. Antiviral effects of sophoridine against coxsackievirus B3 and its pharmacokinetics in rats. Life Sci 78 (2006) 1998-2005
28. Cao Q.Z., and Lin Z.B. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cells. Life Sci 78 (2006) 1457-1463
29. Tong Y.G., Zhang X.W., Geng M.Y., et al. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 69 (2006) 1226-1233
30. Wei G., Ji X., Bai H., and Ding Y. Stroke research in China. Neurol Res 28 (2006) 11-15
31. Zhao Y.N., Pan Y., Tao J.L., Xing D.M., and Du L.J. Study on cardioactive effects of brazilein. Pharmacology 76 (2006) 76-83
32. Wang Y.K., and Huang Z.Q. Protective effects of icariin on human umbilical vein endothelial cell injury induced by H2O2 in vitro. Pharmacol Res 52 (2005) 174-182
33. Kou J., Yu B., and Xu Q. Inhibitory effects of ethanol extract from Radix Ophiopogon japonicus on venous thrombosis linked with its endothelium-protective and anti-adhesive activities. Vascul Pharmacol 43 (2005) 157-163
34. Wu G.D., Zhou H.J., and Wu X.H. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascul Pharmacol 41 (2004) 205-212
35. Cheng T.O., Xie M.X., Wang X.F., Wang Y., and Lu Q. Real-time three-dimensional echocardiography in assessing atrial and ventricular septal defects: an echocardiographic-surgical correlative study. Am Heart J 148 (2004) 1091-1095 [Correction 2005;149:208]
36. Xie M.X., Wang X.F., Cheng T.O., Wang J., and Lu Q. Comparison of accuracy of mitral valve area in mitral stenosis by real-time, three-dimensional echocardiography versus two-dimensional echocardiography versus Doppler pressure half-time. Am J Cardiol 95 (2005) 1496-1499
37. Xie M.X., Wang X.F., Cheng T.O., Lu Q., Yuan L., and Liu X. Real-time 3-dimensional echocardiography: a review of the development of the technology and its clinical application. Prog Cardiovasc Dis 48 (2005) 209-225
38. Cheng T.O. Clinical application of real-time three-dimensional echocardiography. J Cardiol 49 (2007) 213-214
39. Maron B.J. Hypertrophic cardiomyopathy in China. Am J Cardiol 100 (2007) 145-146
40. Shen C.D., Zhang W.L., Sun K., Wang Y.B., Zhen Y.S., and Hui R.T. Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study. Ann Hum Genet (May 22 2007) [Epub ahead of print]
41. Wang S.X., Zou Y.B., Fu C.Y., et al. Family hypertrophic cardiomyopathy caused by a 14035c > t mutation in cardiac troponin T gene. Zhonghua Yixue Zazhi 87 (2007) 371-374
42. Jing Z.C., Xu X.Q., Han Z.Y., et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest (March 30 2007) [Epub ahead of print]
43. Hui R.T. Contemporary diagnosis and treatment of hypertrophic cardiomyopathy. Chin J Cardiol 35 (2007) 82-85
44. Fan X.H., and Hui R.T. Advancement in pharmacogenomics of beta-blocker therapy. Chin J Cardiol 34 (2006) 947-950
45. Pei W.D., Zhang Y.H., Sun Y.H., et al. Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia. Circ J 70 (2006) 1606-1610
46. She H.R., Teng S.Y., Pu J.L., Shang Z.L., and Hui R.T. Electrophysiological characterization of long QT syndrome associated mutations V630A and N633S. Chin J Cardiol 34 (2006) 523-727
47. Wang H., and Hui R.T. Gene mutations and dilated cardiomyopathy. Chin J Cardiol 34 (2006) 193-195
48. Zhang W.L., Zhang H.Y., Sun K., and Hui R.T. Use of unlinked genetic markers to detect population stratification: a case-control multicenter study. Zhonghua Yixue Zazhi 85 (2005) 1185-1189
49. Jing Z.C., Lu L.H., Zou Y.B., et al. Clinical and genetic characteristics of a Chinese family of primary pulmonary hypertension. Zhonghua Yixue Zazhi 84 (2004) 199-202
50. Yang W.J., Huang J.F., Yao L., et al. Evidence for linkage and association of the markers near the LPL gene with hypertension in Chinese families. J Med Genet 40 (2003) e57
51. Chinese PLA Cardiologic Society. The survey on radiofrequency catheter ablation in Chinese military hospitals. Chin J Cardiol 33 (2005) 332-334
52. Cheng T.O., and Guo J.H. Catheter ablation for atrial fibrillation: The Chinese experience. Int J Cardiol 111 (2006) 154
53. Cappato R., Calkins H., Chen S.-A., et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111 (2005) 1100-1105
54. Gao R.L. Current status and perspective of percutaneous coronary intervention in China. Chin Med J 119 (2006) 531-532
55. Cheng T.O. The deteriorating cardiovascular health in China in the past decade. Int J Cardiol 114 (2007) 129
56. Ge L., and Ge J. The reasons coronary heart disease mortality has increased in China. Am Heart Hosp J 5 (2007) 97-99
57. Liu L. Cardiovascular diseases in China. Biochem Cell Biol 85 (2007) 157-163
58. Wu Y., Liu X., Li X., et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 114 (2006) 2217-2225
59. He J., Gu D., Wu X., et al. Major causes of death among men and women in China. N Engl J Med 353 (2005) 1124-1134
60. Wu G., Wu Z., Wang W., et al. A cohort study on trends of cardiovascular disease risk factors in Beijing during 1992-2002. Chin J Cardiol 33 (2005) 748-753
61. Cheng T.O. Fast food and obesity in China. J Am Coll Cardiol 42 (2003) 773
62. Cheng T.O. Diets play a major role in heart disease in China. Lipids 39 (2004) 291-292
63. Cheng T.O. Fast food, automobiles, television and obesity epidemic in Chinese children. Int J Cardiol 98 (2005) 173-174
64. Cheng T.O. Rising incidence of coronary artery disease in China in parallel with rising 'normal' plasma cholesterol levels. Atherosclerosis 173 (2004) 371
65. Cheng T.O. Rising cholesterol levels in China. Int J Cardiol 105 (2005) 332-333
66. Cheng T.O. Effect of rising serum cholesterol on risks of cardiovascular disease in modern China. Int J Cardiol 119 (2007) 1-2
67. Cheng T.O. Television viewing as a global risk factor for childhood obesity. Int J Cardiol 103 (2005) 344
68. Cheng T.O. Price of modernization of China. Circulation 103 (2001) e132
69. Cheng T.O. Diabetes and obesity epidemics in China: a national crisis. Int J Cardiol 123 (2007) 1-2
70. Cheng T.O. An obesity epidemic in modern China. Am J Cardiol 88 (2001) 721-722
71. Cheng T.O. Obesity epidemic in modern China. Int J Cardiol 118 (2007) 397
72. Cheng T.O. Fat kids grow up to be fat adults. A lesson to be learned from China. Int J Cardiol 117 (2007) 133-135
73. Cheng T.O. Obesity is a global challenge. Am J Med 119 (2006) e11
74. Wu Y., et al., for the US-PRC Collaborative Study of Cardiovascular and Cardiopulmonary Epidemiology Research Group and the China Multicenter Collaborative Study of Cardiovascular Epidemiology (China MUCA) Research Group. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 114 (2006) 2217-2225
75. Hu D.Y., Pan C.Y., Yu J.M., and China Heart Survey Group. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 27 (2006) 2573-2579
76. Lin S., Cheng T.O., Liu X., et al. Impact of dysglycemia, body mass index, and waist-to-hip ratio on the prevalence of systemic hypertension in a lean Chinese population. Am J Cardiol 97 (2006) 839-842
77. Cheng T.O. The metabolic syndrome, formerly called metabolic 'syndrome X'. Am J Cardiol 94 (2004) 148-149
78. Cheng T.O. Syndrome X confusion. Physician Sportsmedicine vol. 22(10) (1994) 49
79. Cheng T.O. Cardiac syndrome X versus metabolic syndrome X. Int J Cardiol 119 (2007) 137-138
80. Cheng T.O. Prevalence of metabolic syndrome is still underestimated in the Chinese population. Int J Cardiol 116 (2007) 257-258
81. Cheng T.O. Prevalence of metabolic syndrome in Chinese adults has been underestimated by using U.S.-based National Cholesterol Education Program Adult Treatment Panel III and World Health Organization criteria. Am J Cardiol 98 (2006) 422-423
82. Cheng T.O. Metabolic syndrome in China. Circulation 109 (2004) e180
83. He Y., Jiang B., Wang J., et al. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol 47 (2006) 1588-1594
84. Wang J.J., Li H.B., Kinnunen L., et al. How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population?. Atherosclerosis 192 (2007) 161-168
85. Cheng T.O. Teenage smoking in China. J Adolesc 22 (1999) 607-620
86. Cheng TO. Adolescent smoking in China. Int J Cardiol, in press.
87. Cheng T.O. Smoking and diabetes in Chinese men. Postgrad Med J 77 (2001) 551
88. Jiang Y., Ong M.K., Tong E.K., et al. Chinese physicians and their smoking knowledge, attitudes, and practices. Am J Prev Med 33 (2007) 15-22
89. NIH Roadmap Initiatives. Available at http://nihroadmap.nih.gov/initiatives.asp. Accessed August 3, 2007.
90. Patel D.N., and Bailey S.R. Nanotechnology in cardiovascular medicine. Catheter Cardiovasc Interv 69 (2007) 643-654
91. Sahoo S.K., Parveen S., and Panda J.J. The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnology, Biology, and Medicine vol. 3 (2007) 20-31
92. Bai C. Ascent of nanoscience in China. Science 309 (2005) 61-63
93. Michelson E.S. Nanotechnology policy: an analysis of transnational governance issues facing the United States and China. In: Blanpied W.A., and Gang Z. (Eds). Proceedings of the China-US Forum on Science and Technology Policy (February 2007), George Mason University, Arlington, Va 345-358
94. Zhang Y.D. Application of nanobiological technology in medicine and its advances in China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28 (2006) 579-582
95. Yang C.X., Xu X.H., and Dong Y. Advances in the research on targeted preparations of traditional Chinese medicine and natural drugs. Zhongguo Zhong Yao Za Zhi vol. 28 (2003) 696-700
96. Wickline S.A., Neubauer A.M., Winter P., Caruthers S., and Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 26 (2006) 435-441
97. Hamon M., Lécluse E., Monassier J.-P., Grollier G., and Potier J.-C. Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Drugs Aging 13 (1998) 291-301
98. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55 (2003) 329-347
99. Park K. Nanotechnology: what it can do for drug delivery. J Control Release 120 (2007) 1-3
100. The U.S., Japan, South Korea, and Germany Dominate in Nanotechnology Today - But Taiwan and China Are Rising. New York, NY: Lux Research, Inc., November 3, 2005. Available at www.luxresearchinc.com/press/RELEASE_Nation2.pdf. Accessed August 1, 2007.
101. Stipp D., and Dan Z. Can China overtake the U.S. in science?. Fortune 150 (2004) 187-196
102. Appelbaum RP, Parker RA. Innovation or imitation? China's bid to become a global leader in nanotechnology. Santa Barbara, CA: UCSB Center for Nanotechnology in Society working paper (March 21, 2007).
103. Cheng T.O. A preventable epidemic of coronary heart disease in modern China. Eur J Cardiovasc Prev Rehab 12 (2005) 1-4